Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment
AimElevated neutrophil-to-lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients treated with first-line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed. Methods81 metastatic NSCLC patients harboring EGFR mutation treated with first-line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated. ResultsElevated NLR (3.5) was observed in 33 of 81 patients. The progression-free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P<0.001 and 17.20 vs 23.20 months, P<0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression-free and overall survival in Cox multivariate analysis. ConclusionElevated NLR is likely to be associated with poor outcome in EGFR-mutated advanced NSCLC patients treated with first-line EGFR TKIs.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|4 区医学
小类|4 区肿瘤学
最新[2023]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Sun Yat Sen Univ, Zhongshan City Peoples Hosp, Dept Med Oncol, Zhongshan Hosp, Zhongshan, Peoples R China;
通讯作者：
通讯机构：[3]Sun Yat Sen Univ, Dept Hematol Oncol, Ctr Canc, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China;
推荐引用方式(GB/T 7714)：
Lin Gui-Nan,Peng Jie-Wen,Liu Pan-Pan,et al.Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment[J].ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY.2017,13(5):E189-E194.doi:10.1111/ajco.12273.
APA：
Lin, Gui-Nan,Peng, Jie-Wen,Liu, Pan-Pan,Liu, Dong-Ying,Xiao, Jian-jun&Chen, Xiao-Qin.(2017).Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY,13,(5)
MLA：
Lin, Gui-Nan,et al."Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment".ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 13..5(2017):E189-E194
